Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $8.2 million.

  • Seres Therapeutics' Profit After Tax fell 9075.88% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 12847.34%. This contributed to the annual value of -$125.8 million for FY2024, which is 3385.0% up from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Profit After Tax is $8.2 million, which was down 9075.88% from -$19.9 million recorded in Q2 2025.
  • Seres Therapeutics' 5-year Profit After Tax high stood at $88.8 million for Q3 2024, and its period low was -$71.2 million during Q1 2023.
  • Its 5-year average for Profit After Tax is -$21.1 million, with a median of -$35.5 million in 2021.
  • Per our database at Business Quant, Seres Therapeutics' Profit After Tax soared by 32529.06% in 2021 and then crashed by 18795.63% in 2022.
  • Over the past 5 years, Seres Therapeutics' Profit After Tax (Quarter) stood at -$50.0 million in 2021, then crashed by 37.59% to -$68.8 million in 2022, then soared by 49.54% to -$34.7 million in 2023, then skyrocketed by 54.96% to -$15.6 million in 2024, then surged by 152.47% to $8.2 million in 2025.
  • Its last three reported values are $8.2 million in Q3 2025, -$19.9 million for Q2 2025, and $32.7 million during Q1 2025.